Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer
AstraZeneca, a global, science-led biopharmaceutical company, announced that its Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC …